

ASX ANNOUNCEMENT

BIOSHARES BIOTECH SUMMIT PRESENTATION

Sydney Australia, 18 July 2014: Dr Peter French, CEO and Managing Director of Benitec Biopharma Limited (ASX: BLT, OTC:BTEBY) will deliver a presentation in the “Clinical Trials Review” session tomorrow morning at the Bioshares Biotech Summit in Queenstown, New Zealand.

Investors are invited to view and listen to the presentation that will be delivered during the conference by copying and pasting the following link into a web browser:

<http://www.brrmedia.com/event/124682/>

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington’s disease. For more information on Benitec refer to the Company’s website at www.benitec.com.